Relation of genetic polymorphisms in microRNAs with diastolic and systolic function in type 2 diabetes mellitus

Published:September 12, 2022DOI:


      • MicroRNAs (miRNA) affect the diastolic and systolic function of T2DM.
      • MiR-133a-1 rs8089787 and let-7f rs10877887 associated with cardiac diastolic dysfunction.
      • The impaired diastolic function was reflected as increased LAVI, decreased mean E′ and increased E/E’.
      • The findings may be a promising therapeutic targets for preventing diastolic dysfunction in T2DM subjects.


      Background and aims

      Type 2 diabetes mellitus (T2DM) has high risk of developing cardiac dysfunction, increasing of either cardiovascular death or hospitalization for heart failure. MicroRNAs (miRNA) affect cardiac function of T2DM. The aim of this study was to investigate the relationships between five miRNA single nucleotide polymorphisms (SNP) and diastolic and systolic function of T2DM.

      Methods and results

      Three hundred untreated T2DM subjects were included. Each subject underwent SNP genotyping, conventional echocardiography, tissue doppler imaging, and speckle tracking imaging. The effects of miRNA SNPs on diastolic and systolic function were evaluated. The diastolic function of T2DM subjects with miR-133a-1-rs8089787 wild genotype or let-7f-rs10877887 variant genotype was lower than those with miR-133a-1-rs8089787 variant genotype or let-7f-rs10877887 wild genotype, manifesting as higher left atrial volume index, lower mean E′, and higher E/E’ (P < 0.05). There were no significant effects of miR-133a-2-rs13040413, let-7a-1-rs13293512 and miR-27a-rs895819 on the diastolic function of T2DM subjects (P > 0.05). These five miRNA SNPs had no effect on the systolic function of T2DM subjects (P > 0.05).


      MiRNA-133a-1-rs8089787 and let-7f-rs10877887 were associated with impaired cardiac diastolic function in T2DM. The findings may be a promising therapeutic targets for preventing diastolic dysfunction in T2DM.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Nutrition, Metabolism and Cardiovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dunlay S.M.
        • Givertz M.M.
        • Aguilar D.
        • Allen L.A.
        • Chan M.
        • Desai A.S.
        • et al.
        Type 2 diabetes mellitus and heart failure: A scientific statement from the American heart Association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.
        Circulation. 2019; 140: e294-e324
        • Chen S.
        • Puthanveetil P.
        • Feng B.
        • Matkovich S.J.
        • Dorn 2nd, G.W.
        • Chakrabarti S.
        Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes.
        J Cell Mol Med. 2014; 18: 415-421
        • Delaunay M.
        • Osman H.
        • Kaiser S.
        • Diviani D.
        The role of cyclic AMP signaling in cardiac fibrosis.
        Cells. 2019; 9: 69
        • Marin-Royo G.
        • Ortega-Hernandez A.
        • Martinez-Martinez E.
        • Jurado-Lopez R.
        • Luaces M.
        • Islas F.
        • et al.
        The impact of cardiac lipotoxicity on cardiac function and mirnas signature in obese and non-obese rats with myocardial infarction.
        Sci Rep. 2019; 9: 444
        • Qin X.D.
        • Liu L.
        Loss of microRNA-27a induces cardiac dysfunction through activating FoxO1.
        Eur Rev Med Pharmacol Sci. 2019; 23: 5941-5948
        • Zhou P.P.
        • Li Y.
        • Ma Z.D.
        • Li Z.Y.
        • Chen F.Y.
        • Jiang Y.X.
        Single nucleotide polymorphisms in the promoter region of mir-133a-1 and in pre-mir-152 rs1707 may contribute to the risk of asthma in a Chinese Han population.
        Eur Rev Med Pharmacol Sci. 2016; 20: 2642-2649
        • Ohanian M.
        • Humphreys D.T.
        • Anderson E.
        • Preiss T.
        • Fatkin D.
        A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance.
        BMC Genet. 2013; 14: 18
        • Zhang L.
        • Yang J.
        • Xue Q.
        • Yang D.
        • Lu Y.
        • Guang X.
        • et al.
        An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic stroke.
        J Thromb Thrombolysis. 2016; 42: 610-615
        • Yan Y.X.
        • Wu L.J.
        • Zhang J.
        • Wang S.
        • Wang W.
        • Dong J.
        • et al.
        Let-7 related genetic variation and risk of metabolic syndrome in a Chinese population.
        Endocr J. 2015; 62: 887-896
        • Dong H.
        • Huang Z.
        • Zhang H.
        • Xiao Z.
        • Liu Q.
        Rs13293512 polymorphism located in the promoter region of let-7 is associated with increased risk of radiation enteritis in colorectal cancer.
        J Cell Biochem. 2018; 119: 6535-6544
        • Liu J.
        • Ni S.
        Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma.
        Gene. 2018; 642: 256-260
        • Cai M.Y.
        • Cheng J.
        • Zhou M.Y.
        • Liang L.L.
        • Lian S.M.
        • Xie X.S.
        • et al.
        The association between pre-miR-27a rs895819 polymorphism and myocardial infarction risk in a Chinese Han population.
        Lipids Health Dis. 2018; 17: 7
        • Ghaedi H.
        • Tabasinezhad M.
        • Alipoor B.
        • Shokri F.
        • Movafagh A.
        • Mirfakhraie R.
        • et al.
        The pre-mir-27a variant rs895819 may contribute to type 2 diabetes mellitus susceptibility in an Iranian cohort.
        J Endocrinol Invest. 2016; 39: 1187-1193
        • Yu X.Y.
        • Chen H.M.
        • Liang J.L.
        • Lin Q.X.
        • Tan H.H.
        • Fu Y.H.
        • et al.
        Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor.
        PLoS One. 2011; 6e16239
        • Chien C.Y.
        • Wen T.J.
        • Cheng Y.H.
        • Tsai Y.T.
        • Chiang C.Y.
        • Chien C.T.
        Diabetes upregulates oxidative stress and downregulates cardiac protection to exacerbate myocardial ischemia/reperfusion injury in rats.
        Antioxidants. 2020; 9: 679
        • Heinonen I.
        • Sorop O.
        • van Dalen B.M.
        • Wust R.C.I.
        • van de Wouw J.
        • de Beer V.J.
        • et al.
        Cellular, mitochondrial and molecular alterations associate with early left ventricular diastolic dysfunction in a porcine model of diabetic metabolic derangement.
        Sci Rep. 2020; 1013173
        • Yildirim S.S.
        • Akman D.
        • Catalucci D.
        • Turan B.
        Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1.
        Cell Biochem Biophys. 2013; 67: 1397-1408
        • Chavali V.
        • Tyagi S.C.
        • Mishra P.K.
        MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes.
        Biochem Biophys Res Commun. 2012; 425: 668-672
        • Avgeris M.
        • Kokkinopoulou I.
        • Maratou E.
        • Mitrou P.
        • Boutati E.
        • Scorilas A.
        • et al.
        Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome.
        Diabetes Res Clin Pract. 2020; 164108187
        • Rijzewijk L.J.
        • van der Meer R.W.
        • Smit J.W.
        • Diamant M.
        • Bax J.J.
        • Hammer S.
        • et al.
        Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus.
        J Am Coll Cardiol. 2008; 52: 1793-1799